hotspot -WSS

hotspot

author：comprehensive 2025-09-27 19:21:23 - browse：15314

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Wildfire pollution widens asthma inequities on Long Island

WSS

Curing rare childhood diseases will falter unless Congress steps up

Curing rare childhood diseases will falter unless Congress steps up

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Adults seen as increasingly susceptible to measles

Amazon expands telehealth clinic nationwide

The system is set up to fail children with medical complexity

focus

hotspot

focus

Psychedelics group wrestles with new pharma identity

Trump indictment: Who are the 'co

Guidelines to prevent youth baseball injuries need more muscle

Moderna says combo Covid

State Dept. review finds Biden bears some blame for Afghanistan failures

Trump indictment: Who are the 'co

Medical leaders decry Supreme Court decision on affirmative action

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Activists slam private health insurers over coverage restrictions

Medical device trials still don't enroll enough women, study finds

hotspot

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Mitch McConnell episode has important public health takeaway

STAT Virtual Event: ASCO Recap, Live!

New safety details link Apellis eye drug to rare cases of blindness

The high personal cost of affirmative action for Black doctors

‘Oppenheimer’ and the risks of AI in health care

leisure time

Wikipedia

knowledge

explore